Schwannomas
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent (NCT06322342) | Reveal Pharmaceuticals Inc. | 2024-08-15 |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (NCT05684692) | Massachusetts General Hospital | 2023-08-31 |
| Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET (NCT03542773) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-02-06 |
Track Schwannomas automatically
Every clearance here is in the API, with alerts when new ones post.